Arcellx (ACLX) Non-Current Deffered Revenue (2021 - 2025)
Arcellx (ACLX) recorded quarterly Non-Current Deffered Revenue of $53.1 million in Q4 2025, up 1.28% quarter-over-quarter from $52.4 million in Q3 2025, and down 30.13% on a YoY basis from $76.0 million in Q4 2024.
Arcellx (ACLX) Non-Current Deffered Revenue (2021 - 2025) Analysis & Trends
Arcellx's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $53.1 million for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue fell 30.13% year-over-year to $53.1 million; the TTM figure through Dec 2025 stood at $53.1 million (down 30.13% YoY), while the FY2025 annual figure was $53.1 million, down 30.13% from the prior year.
- Non-Current Deffered Revenue was $53.1 million for Q4 2025 at Arcellx, up from $52.4 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $170.7 million in Q4 2023 to a low of $1.9 million in Q4 2021.
- Historically, Non-Current Deffered Revenue has averaged $86.6 million across 4 years, with a median of $82.6 million in 2024.
- Biggest YoY gain for Non-Current Deffered Revenue was 5.96% in 2024; the steepest drop was 55.47% in 2024.
- A 4-year view of Non-Current Deffered Revenue shows it stood at $1.9 million in 2021, then jumped by 8906.49% to $170.7 million in 2023, then slumped by 55.47% to $76.0 million in 2024, then sank by 30.13% to $53.1 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $53.1 million (Q4 2025), $52.4 million (Q3 2025), and $59.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 53.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.10 Mn |
| Sep 30, 2025 | 52.43 Mn |
| Jun 30, 2025 | 59.92 Mn |
| Mar 31, 2025 | 69.45 Mn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 82.61 Mn |
| Jun 30, 2024 | 96.08 Mn |
| Mar 31, 2024 | 112.07 Mn |
| Dec 31, 2023 | 170.67 Mn |
| Sep 30, 2023 | 121.09 Mn |
| Jun 30, 2023 | 124.27 Mn |
| Mar 31, 2023 | 105.76 Mn |
| Dec 31, 2021 | 1.90 Mn |